# RECENT ADVANCES IN IMAGING OF PEDIATRIC MUSCULOSKELETAL TUMORS

Essay
Submitted for partial fulfillment of the Msc. Degree in Diagnostic Radiology

Yasser Mohammed Mustafa Mahfouz M.B., B.CH

Under supervision of

#### Prof.Dr. Essam Aly Elshiekh

Prof.Dr. Maha Hussien Helal

Professor of Diagnostic Radiology
Faculty of medicine
Cairo University

Professor of Diagnostic Radiology
National Cancer Institute
Cairo University

Cairo University 2008

## **ACKNOWLEDGEMENT**

First and foremost I thank Allah the most merciful who indebted me with his countless blessings.

I would like to express my special thanks and deep gratitude to Prof. Dr. Esam El-Shiekh, professor of diagnostic radiology, Faculty of medicine-Cairo University-for the science that he has been delivering to candidates over years. For his sincere help, guidance and for the time spent on this essay.

My gratitude to my mentor and professor Prof. Dr. Maha Helal, professor of diagnostic radiology, National Cancer Institute-Cairo University-for for her unfailing patience, tolerance and generosity. For her outstanding humbleness that parallels her invaluable knowledge. For the delightful work atmosphere she creates and the kindest patronage.

I would like to express my deep gratitude to my professors, my colleagues and co workers who aids me to finish this work.

## **DEDICATION**

To my parents, sister, brother and of course my wife and kids for the unconditioned love and support.

## TABLE OF CONTENTS

Acknowledgement & Dedication		
Table of Contents		
List of Abbreviations	IV	
List of Figures	VI	
• List of Tables	IX	
• Introduction	1	
Review of Literature:		
> Chapter one: Clinical and pathological overview	6	
Chapter two: Plain radiography	19	
> Chapter three: Multidetector computed tomography	27	
Chapter four: Magnetic resonance imaging	37	
DCE-MRI	52	
• DWI	64	
• MRS	77	
Chapter five: Positron emission tomography	90	
Summary and Conclusion		
• References		
Arabic Summary		

## LIST OF ABBREVIATIONS

**ACR** American College of Radiology

**ADC** Apparent Diffusion Coefficient AT Acquisition time BC Bone cyst **CB** Chondroblastoma **CCH-E** Children's Cancer Hospital-Egypt Cho Choline **CNR** Contrast to Noise Ratio **CS** Chondrosarcoma **CT** Computed Tomography **DCE-MRI** Dynamic contrast material-enhanced MR **DWI** Diffusion weighted MRI EC Enchondroma ES Ewing's sarcoma **FD** Fibrous dysplasia FDG 2-[fluorine 18]-fluoro-2-deoxy-D-glucose FFE Fast-Field-Echo **FOV** Field of view FSE Fast Spin Echo **FSPGR** Fast spoiled **GCT** Giant cell tumor Gd Gadolinium **GRASS** Gradient-recalled echo in the steady state **GRE** Gradient Recalled Echo **HA** Hemangioma **HIS** Hospital Information System **IVIM** Intra Voxel Incoherent Motion **LCH** Langerhans cell histiocytosis mAs milliampere-second MDCT Multi Detector Computed Tomography MIBG Iodine-131-meta-iodobenzylguanidine ML Malignant lymphoma MPR Multiplanar reconstruction MPR Multiplaner reformatting images MR Magnetic Resonance MRS Magnetic Resonance Spectroscopy MRSI Multivoxel Spectroscopic imaging MSK Musculoskeletal system **NOF** Nonossifying fibroma OC Osteochondroma **OO** Osteoid osteoma **OSA** Osteosarcoma **PACS** Picture Archiving and Communication System **PD** Proton Density **PET** Positron emission tomography RF-FAST Radio Frequency Spoiled Fourier-acquired steady-state technique

- **RIS** Radiology Information System
- **ROI** Region of Interest
  - **SA** Sarcoidosis
  - **SE** Spin echo
  - SI Signal Intensity
- **SNR** Signal to Noise Ratio
- **SPECT** Single Photon Emission Computed Tomography
- SP-GR Spoiled gradient echo
  - **SSD** Shaded Surface Display
  - STIR Short tau Inversion Recovery
  - SUV Standardized uptake value
    - **SV** Single voxel
      - T Tesla
  - T1-W T1-weighted
  - **T2-W** T2-weighted
  - **TBR** Tumor to background ratio
  - **TSE** Turbo-spin-echo
  - VIBE Volumetric Interpolated Breath hold Examination
    - **VR** Volume rendering
    - **3D** Three dimensional

# LIST OF FIGURES

FIG	Title	PAGE
No		PAGE
FIG 1.1	Five-year survival rates among children and adolescents with Rhabdomyosarcoma, Osteosarcoma and Ewing's Sarcoma	7
FIG 1.2	The common primary sites of the tumor and age distribution	11
FIG 2.1	Different patterns of bone destruction	21
FIG 2.2	Ewing's sarcoma showing permeative bone lesion.	22
FIG 2.3	non-ossifying fibroma showing geographic bone destruction	22
FIG 2.4	Different patterns of periosteal reaction	23
FIG 2.5	parosteal osteosarcoma showing speculated aggressive looking periosteal reaction	23
FIG 2.6	Typical appearance of a fibrous cortical defect. Enneking stage 0.	24
FIG 2.7	Typical appearance of a unicameral bone cyst. Enneking stage 2	24
FIG 2.8	Radiographic features of an aggressive osteosarcoma. Enneking stage 2B.	26
FIG 3.1	64MDCT image of a patient with right mandibular adamantinoma	28
FIG 3.2	MDCT image of a patient with sacral osteosarcoma	32
FIG 3.3	MDCT image of a patient with metastatic retinoblastoma to the zygomatic bone	33
FIG 3.4	MDCT image of a patient with fibrous cortical defect	33
FIG 3.5	MDCT image of orthopedic hardware in patient with polyostotic fibrous dysplasia	35
FIG 3.6	CT angiography of both lower limbs	36
FIG 4.1-a	Coronal T1-W image of discoid lateral meniscus	38
FIG 4.1-b	Coronal STIR image of discoid lateral meniscus	38
FIG 4.1-c	Sagittal fast/turbo spin-echo T2-W image with fat suppression of discoid lateral meniscus.	39
FIG 4.1-d	Sagittal fast/turbo spin-echo intermediate-weighted image with fat suppression of discoid lateral meniscus	39
FIG 4.2	Preossification changes in the epiphyseal cartilage	40
FIG 4.3	Coronal T1-W GRE image of the proximal right femur	41
FIG 4.4	Epiphyseal marrow transformation depicted on coronal T1-W images of the proximal femoral epiphysis	43
FIG 4.5	Sagittal T1-W image of the humerus of a patient with Ewing sarcoma	45
FIG 4.6	Sagittal fast/turbo spin echo T2-W sequence with fat suppression and STIR sequence for a patient with osteosarcoma	46

FIG	Title	DACE
No		PAGE
FIG 4.7	Morphological changes in an 8-year-old girl with a tibial osteosarcoma in the right leg	51
FIG 4.8	Schematic pathway of i.v. injected extracellular contrast agent through malignant tissue	53
FIG 4.9	DCE-MRI in a patient with a large osteosarcoma of the proximal tibia	56
FIG 4.10	Schematic of the angiogenic effects of therapy response relevant for functional imaging with low molecular weight Gd-chelate contrast agents	59
FIG 4.11	Monitoring neoadjuvant chemotherapy with functional MRI in a young patient with an osteosarcoma of the lower arm	60
FIG 4.12	Monitoring therapeutic effect with functional and conventional MRI in a 14-year old girl with left leg osteosarcoma	62
FIG 4.13	Diffusion pathways in vivo	65
FIG 4.14	Drawing to illustrate restricted diffusion in a tumor and not restricted diffusion in benign tissue	67
FIG 4.15	Progressive age-related diffusion changes in normal epiphyses	70
FIG 4.16	ADC map shows restricted diffusion within a growing mass on the right thigh (fibrosarcoma)	71
FIG 4.17	Graph comparing changes in the apparent diffusion coefficient (ADC) value before and after therapy	74
FIG 4.18	Monitoring therapeutic effect with ADC in a 14-year-old girl with Osteosarcoma	75
FIG 4.19	MR spectrum (single-voxel, TR/TE 2000/144) obtained from single-voxel spectroscopy of an area of skeletal muscle	77
FIG 4.20	Single-voxel spectroscopy (single-voxel, TR/TE 2000/144) performed on an indeterminate right iliac bone lesion	78
FIG 4.21	Multivoxel proton MR spectroscopic imaging (MRSI, TR/TE 2000/144) performed on an indeterminate left humeral mass	79
FIG 4.22	MRS of a patient with a lipoma of the left forearm	81
FIG 4.23	MRS and conventional sequences of a patient with right thigh low grade sarcoma	82
FIG 4.24	Spectra were acquired at different TEs in a patient with lymphoma	83
FIG 4.25	Spectra acquired at different TEs in a patient with intramuscular hemangioma	84
FIG 4.26	Spectra for a patient with GCT of the distal radius	85
FIG 4.27	False-positive spectra acquired at different TEs in a patient with extensive abscess of thigh	86
FIG 4.28	False-negative spectra acquired at different echo times in patient with intensely ossified parosteal osteosarcoma	87
FIG 4.29	The proton MRS changes of a patient with lymphoma after 8 courses of chemotherapy	89
FIG 5.1	Positron and annihilation radiation	90
FIG 5.2	Coincidence detection system	91

FIG	Title	PAGE
No		IAGE
FIG 5.3	[18F]2-deoxy-2-fluoro-d-glucose (FDG)	93
FIG 5.4	FDG metabolism	93
FIG 5.5	Transverse CT & PET/CT images in 16-year-old adolescent boy with osteosarcoma in tibia	95
FIG 5.6	18FDG whole body PET scan of an 8-year-old girl following distal right femoral allograft for osteogenic sarcoma	98
FIG 5.7	18FDG whole body PET scans of a 9-year-old girl with Ewing sarcoma of the right ilium	98
FIG 5.8	18FDG PET scan of an aggressive recurrent osteoblastoma in a 17-year-old male 11 months after previous surgery	99
FIG 5.9	Standardized uptake values (SUV) of primary bone tumors	100
FIG 5.10	FDG PET of musculoskeletal neoplasms	101
FIG 5.11	An example of pre- and postchemotherapy FDG PET images in two different patients with osteosarcoma	102
FIG 5.12	FDG PET/CT image shows no significant activity in the region of patient's treated Ewing sarcoma despite persistent findings on MRI	102
FIG 5.13	Standardized uptake values (SUV) in relation to grade of bone and soft tissue sarcomas	105
FIG 5.14	Effects of granulocyte colony-stimulating factor and radiation on FDG uptake	108
FIG 5.15	Anterior maximal intensity projection images of a 12-yearold boy undergoing therapy with markedly increased uptake in the thymus, which appears enlarged	109
FIG 5.16	PET scan of a patient with avulsive cortical irregularity	110

# LIST OF TABLES

Table No		PAGE
1.1	Classification of pediatric musculoskeletal tumors based on tissue of origin	6
1.2	Peak age of common pediatric musculoskeletal tumors	8
1.3	Enneking system for surgical staging of malignant bone and soft tissue tumors	15
1.4	Enneking system for surgical staging of benign bone lesions	15
1.5	Current treatment principles of malignant bone tumors of childhood	18
2.1	Common locations of pediatric bone tumors	20
3.1	Suggested protocols for MDCT for evaluation of musculoskeletal disease in the pediatric patient	30
3.2	Specific features of pediatric musculoskeletal tumors and tumor like conditions	34
4.1	Basic routine MR protocol for long-bone malignant tumors	54
5.1	Values for overall staging of MSK tumors with different modalities	106
6.1	A suggested summary by the ACR of appropriate radiologic examination procedures for evaluation of bone tumors	117

## **ABSTRACT**

The development of more effective chemotherapeutic agents as well as improvement in limb salvage surgery and advances in radiotherapy assisted by novel technologies of the imaging techniques have improved staging and ultimate outcome in pediatric patients with musculoskeletal tumors.

The role of medical imaging in diagnosis, staging and eventual follow up of these patients has expanded; in particular the recent applications of MRI specially the functional imaging, as well as the PET/CT and MDCT technologies trying to reach the best way for management of such tumors in that age .

**Key words:** pediatric, musculoskeletal, tumors, MDCT, DWI, DCE-MRI, MRS, PET/CT.

### **INTRODUCTION**

Pediatric musculoskeletal tumors are uncommon, and when they occur, are usually benign. Early detection of a malignant musculoskeletal tumor may not only make the difference between life and death, but also may allow for successful limb salvage surgery rather than amputation of the limb. (*Erol et al. 2004*)

Before the development of adjuvant/neoadjuvant chemotherapy, even localized potentially curable bone tumors had a greater than 80% mortality rate. Multi-agent chemotherapy has resulted in cures for a significant percentage of patients but there are still failures (\*30–50%) (*Domb et al. 2004*). In addition, chemotherapy is associated both with the development of drug-resistant types and with toxicity. An early predictor of response to chemotherapy would be extremely valuable, allowing the oncologist to intervene with alternative therapies. (*Teo et al. 2007*)

Also there has been an unprecedented improvement in the survival outcome of children with extremity sarcoma as well as a corresponding increase in percentage of limb-sparing surgeries being performed over the past many decades. This has been, in part, due to the improved imaging modalities, newer surgical techniques, and advances in neoadjuvant chemotherapy. (*Conrad et al. 2007*)

Plain radiography is the initial imaging modality in the evaluation of bone tumors. Improvement in the treatment and outcome of patients with bone and soft-tissue tumors requires the development of diagnostic tools that can help differentiate between benign, malignant and malignant mimicking lesions in a noninvasive and reliable manner. The current challenge for imaging is to define new treatment response criteria and to identify new prognostic factors. (*Gregory et al. 2006*)

Some of the developing modalities in this field are multidetector computed tomography (MDCT), dynamic contrast material-enhanced MR (DCE-MRI), diffusion weighted MRI (DWI), MR spectroscopy (MRS) and 18-fluorodeoxyglucose positron emission tomography (18 FDG-PET/CT).

The introduction of multidetector CT is especially valuable in the pediatric patient on a number of levels. First, the tremendous speed of image acquisition with multidetector CT enables the successful completion of most studies in less than 10 seconds is particularly advantageous compared with performing magnetic resonance (MR) imaging in the pediatric patient. Second, with multidetector CT, isotropic volume image data are acquired and the ability to retrospectively reconstruct multiple high-resolution image sets from the original raw data is possible, thereby requiring only one acquisition for production of three-dimensional (3D) CT images in numerous planes. Finally, when used correctly, 3D CT volume imaging can help minimize the radiation dose to the pediatric patient. (*El-Khoury et al 2004*)

Use of multidetector CT has specific advantages that include the ability to combine volume acquisitions with CT angiography for better definition of tumor vascularity and to define involvement of adjacent structures, including blood vessels and muscle. Also its ability to distinguish true neoplasms from processes that mimic tumors, such as osteomyelitis, myositis ossificans, and fractures. Multidetector CT with postprocessing of the data set by using multiplaner reformatting images (MPR) and 3D volume rendering (VR) is valuable in the postoperative

patient with orthopedic hardware in place, as it is capable of potentially eradicating streak artifact associated with metal devices (*Mori et al. 2005*).

Multidetector CT can be used to evaluate the success of intervention as well as determine the etiology of any new symptoms or complaints. Multidetector CT really has unique imaging capabilities that are advantageous in the pediatric population. (*Mahesh 2002*)

The effectiveness of magnetic resonance (MR) imaging in accurate characterization of musculoskeletal tumors has not gone unquestioned (*Jaarmello & Laor 2008*). During the past few years, differentiation between benign and malignant masses on unenhanced MR images has been based mainly on the evaluation of morphologic parameters such as size, demarcation of margins, involvement of adjacent vital structures, signal homogeneity, and measurements of relaxation times (*Chapman et al. 2004*). Contrast-enhanced magnetic resonance imaging (MRI) has proven to be the method of choice for a proper estimation of the extent of bone tumors. (*Varich et al. 2000*)

Contrast-enhanced MR imaging, however, does not allow an optimal estimation of the response to preoperative chemotherapy in the case of osteo- or Ewing's sarcoma, as this technique is unable to visualize small, scattered foci of residual tumor. (*Pui et al. 2005*)

Dynamic contrast-enhanced MR imaging using an intravenous contrast tracer is a sensitive indicator for the presence of remnants of viable tumor in patients with high-grade musculoskeletal tumors (*Verstraete et al. 2005*). In dynamic gradient-echo MR studies, this technique provides clinically useful information by depicting tissue

vascularization and perfusion, capillary permeability, and composition of interstitial space. (*Brisse et al. 2004*)

In addition to imaging features, information regarding the cellular chemistry obtainable from hydrogen 1 (1H) nuclear MR spectroscopy and DWI may help characterize suspicious lesions and assess treatment response. (*Madhu et al. 2006*)

Positron emission tomography (PET) was developed in the 1960s. In recent years, it has been increasingly used in some centers for the detection and staging of malignancy. PET can be used to image tumor metabolism because of the detection of photons emitted from tissue after the intravenous injection of a pharmaceutical such as 2-[fluorine 18]-fluoro-2-deoxy-D-glucose (FDG). (*Aoki et al. 2003*)

PET has been shown to have sensitivity similar to that of serial CT and MR for detecting lesions and for distinguishing post surgical scarring from tumor recurrence. However, the specificity of PET is higher than that of serial CT or MRI. In evaluating musculoskeletal sarcomas, FDG image higher sensitivity, specificity, positive and negative predictive values for detecting recurrent tumor compared with iodine-131-meta-iodobenzylguanidine (MIBG) scans. (*Hawkins et al. 2005*)

PET appears to be better than CT and MRI in depicting residual or recurrent tumor after treatment. The main disadvantage of PET is the high cost of the equipment, which limits its wide availability. (*Biswal et al. 2007*)

The purpose of this study is to review the role of the recent updated imaging modalities used in evaluating the pediatric musculoskeletal tumors and how they can improve the outcome and add new prognostic values by helping in finding a non-invasive trustable method to